Unichem Laboratories

Unichem Laboratories was founded in 1944 by Padmabhushan Late Mr. Amrut V Mody, a pioneer in the Indian pharmaceuticals business. The initial public offering of Unichem Laboratories Limited was in 1963, and the company was consequently listed on BSE Limited and NSE Limited.

It is one of India's oldest and largest pharmaceutical companies, headquartered in Mumbai, Maharashtra, India. Unichem is an international, business-oriented, integrated, specialty pharmaceutical company known for its quality and reliability. It manufactures and markets a large basket of pharmaceutical formulations across the globe, including the regulated markets of the US and Europe.

Unichem Laboratories Limited is currently active in finished formulations, APIs, contract manufacturing, custom synthesis etc. Their R & D site at Goa has expertise in product development, process chemistry and developing complex APIs for global market.

Operations
Unichem's Formulations manufacturing facilities are located at Goa, Ghaziabad (Uttar Pradesh) and Baddi (Himachal Pradesh). Active Pharmaceutical Ingredient (API) manufacturing facilities are located at Roha (Maharashtra), Pithampur (Madhya Pradesh) and Kolhapur (Maharashtra). Out of the 6 Manufacturing Sites, 4 are USFDA approved and have approvals from other major health authorities.

The Company's facilities have been approved by various International health authorities such as USFDA, UK MHRA, ANVISA (Brazil), COFEPRIS (Mexico), PMDA (Japan), TGA (Australia), SAPHRA (South Africa) and MFDS(Korea), EDQM (European Directorate for the Quality of Medicines), TPD (Canada).

Research and Development
Unichem is an R&D driven pharmaceutical Company. R&D is an integral part of the Company's future growth strategy. The Company has set up a state of the art Research & Development Centre known as the ‘Centre of Excellence’ at Goa. The R&D Centre concentrates on developing NDDS for generic APIs and NCEs, reverse engineering the API processes, drug discovery and bio catalysis. The Company has strategic alliances with global players for CRAMS and other projects. The Company has a functional Biotech R&D Centre and a state of art Pilot Plant at Goa. Bio-similar R&D is based on recombinant DNA platform. Microbial fermentation and protein purification are its strengths. The cell culture facility in the Biotech R&D is capable of handling mammalian cell lines for screening novel biological and chemical entities.

The Company has made more than 500 product registrations across the world. It has more than 63 US ANDA filings, 34 approved ANDAs and more than 60 European submissions. The Company holds more than 70 US DMF, 27 Certificate of suitability to European Pharmacopeia (CEP) issued by the European Directorate for the Quality of Medicines and Healthcare (EDQM) and several DMFs across the world.